Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Weinstock

Showing results (81-90 of 172) with videos related to

Pageof 18
Sort By:
Blood|April 10, 2013
PARP1 is required for chromosomal translocationsJustin Wray, Elizabeth A Williamson, Sudha B Singh, et al.
Nature Communications|June 14, 2017
Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNATovah A Day, Jacob V Layer, J Patrick Cleary, et al.
Nature Communications|April 28, 2017
PARP3 is a promoter of chromosomal rearrangements and limits G4 DNATovah A Day, Jacob V Layer, J Patrick Cleary, et al.
Blood Advances|January 4, 2018
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunitiesElizabeth A Morgan, M Patrick Sweeney, Tamiwe Tomoka, et al.
The Journal of Investigative Dermatology|June 2, 2018
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg TypeXiaolong Alan Zhou, Abner Louissaint, Alexander Wenzel, et al.
Disaster Medicine and Public Health Preparedness|March 16, 2011
Scarce resources for nuclear detonation: project overview and challengesC Norman Coleman, Ann R Knebel, John L Hick, et al.
Blood Advances|May 14, 2021
Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countriesFabiola Valvert, Oscar Silva, Elizabeth Solórzano-Ortiz, et al.
British Journal of Haematology|December 30, 2021
The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cellsSarah Haebe, William Keay, Stefan Alig, et al.
Oncotarget|September 9, 2017
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinaseEllen L Weisberg, Alexandre Puissant, Richard Stone, et al.
Cell Reports|January 18, 2016
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian CancerYoung Eun Choi, Khyati Meghani, Marie-Eve Brault, et al.
Pageof 18

Showing results (81-90 of 172) with videos related to

Sort By:
Pageof 18
Blood|April 10, 2013
PARP1 is required for chromosomal translocationsJustin Wray, Elizabeth A Williamson, Sudha B Singh, et al.
Nature Communications|June 14, 2017
Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNATovah A Day, Jacob V Layer, J Patrick Cleary, et al.
Nature Communications|April 28, 2017
PARP3 is a promoter of chromosomal rearrangements and limits G4 DNATovah A Day, Jacob V Layer, J Patrick Cleary, et al.
Blood Advances|January 4, 2018
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunitiesElizabeth A Morgan, M Patrick Sweeney, Tamiwe Tomoka, et al.
The Journal of Investigative Dermatology|June 2, 2018
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg TypeXiaolong Alan Zhou, Abner Louissaint, Alexander Wenzel, et al.
Disaster Medicine and Public Health Preparedness|March 16, 2011
Scarce resources for nuclear detonation: project overview and challengesC Norman Coleman, Ann R Knebel, John L Hick, et al.
Blood Advances|May 14, 2021
Low-cost transcriptional diagnostic to accurately categorize lymphomas in low- and middle-income countriesFabiola Valvert, Oscar Silva, Elizabeth Solórzano-Ortiz, et al.
British Journal of Haematology|December 30, 2021
The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cellsSarah Haebe, William Keay, Stefan Alig, et al.
Oncotarget|September 9, 2017
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinaseEllen L Weisberg, Alexandre Puissant, Richard Stone, et al.
Cell Reports|January 18, 2016
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian CancerYoung Eun Choi, Khyati Meghani, Marie-Eve Brault, et al.
Pageof 18